Catalysts for Janssen Therapeutics
248 tracked
Apr 17, 2026
drug shortage
Methylphenidate Hydrochloride Tablet, Extended Release shortage — Janssen Pharmaceuticals
Janssen Therapeutics
→
Apr 13, 2026
approval
SPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Apr 10, 2026
approval
CONCERTA (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Mar 24, 2026
approval
XARELTO (RIVAROXABAN) — FDA approval
Janssen Therapeutics
→
Mar 24, 2026
approval
XARELTO (RIVAROXABAN) — FDA approval
Janssen Therapeutics
→
Mar 6, 2026
approval
TOPAMAX (TOPIRAMATE) — FDA approval
Janssen Therapeutics
→
Mar 6, 2026
approval
TOPAMAX SPRINKLE (TOPIRAMATE) — FDA approval
Janssen Therapeutics
→
Feb 2, 2026
approval
CONCERTA (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Feb 2, 2026
approval
CONCERTA (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Feb 2, 2026
approval
CONCERTA (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Jan 23, 2026
approval
SPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Oct 30, 2025
approval
HALDOL (HALOPERIDOL DECANOATE) — FDA approval
Janssen Therapeutics
→
Oct 9, 2025
approval
SPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Sep 23, 2025
approval
CONCERTA (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Jul 31, 2025
approval
SPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Jun 17, 2025
approval
XARELTO (RIVAROXABAN) — FDA approval
Janssen Therapeutics
→
Jun 17, 2025
approval
XARELTO (RIVAROXABAN) — FDA approval
Janssen Therapeutics
→
May 15, 2025
approval
SPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Apr 28, 2025
approval
SPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Mar 24, 2025
approval
SPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Mar 12, 2025
approval
TOPAMAX (TOPIRAMATE) — FDA approval
Janssen Therapeutics
→
Mar 12, 2025
approval
TOPAMAX SPRINKLE (TOPIRAMATE) — FDA approval
Janssen Therapeutics
→
Jan 22, 2025
approval
HALDOL (HALOPERIDOL DECANOATE) — FDA approval
Janssen Therapeutics
→
Jan 17, 2025
approval
SPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Dec 31, 2024
approval
SPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Nov 4, 2024
approval
SPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Oct 18, 2023
approval
SPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
Oct 13, 2023
approval
CONCERTA (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
Janssen Therapeutics
→
May 3, 2023
approval
TOPAMAX (TOPIRAMATE) — FDA approval
Janssen Therapeutics
→
May 3, 2023
approval
TOPAMAX SPRINKLE (TOPIRAMATE) — FDA approval
Janssen Therapeutics
→